Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04681482 · ClinicalTrials.gov registry record
Effectiveness And Safety Of Oral Anticoagulants Among Obese Patients With Non-Valvular A-Fib In VA Patients With Medicare
A clinical trial, sponsored by Pfizer.
- Completed
- Registry status
- 107,383
- Enrollment target
NCT04681482: Completed study, sponsored by Pfizer.
NCT04681482 is a clinical trial that has completed, run by Pfizer. The registered enrollment target is 107,383 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04681482 has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- 107,383 participants
- Enrollment target
Study Summary
The overall objective of this analysis is to understand patient characteristics, the use of treatment, and clinical outcomes among obese (overweight) and severely obese patients with non-valvular atrial fibrillation (NVAF) who initiate therapy with OACs (oral anti-coagulants). The aim of this study is to compare all DOACs (direct oral anti-coagulants) to warfarin. However, the primary analysis will be conducted among apixaban vs warfarin patients only. If sample size permits, we will also conduct other DOAC vs warfarin and DOAC vs DOAC analysis.
Primary Outcome
Event rate per 100 participant-years for first occurrence of major bleeding (MB) event after index date in obese participants was reported. MB after index date was identified using hospital claims and occurred anytime during the follow-up period of drug use or within 30 days from the last day of treatment prescription. Index date was defined as date of first DOAC pharmacy claim date during the identification period (July 1, 2013-December 31, 2017 \[3.5 years\]). The first warfarin prescription d
Interventions
- DRUG Apixaban
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 107,383 participants |
| Start Date | 2020-11-02 |
| Est. Completion | 2020-11-03 |
What the finished NCT04681482 record still lists
NCT04681482 is an observational study that tracks outcomes without assigning an intervention. Its 107,383 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 1 intervention - of which Apixaban is the first listed.
NCT04681482 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04681482 about?
NCT04681482 is a clinical study titled "Effectiveness And Safety Of Oral Anticoagulants Among Obese Patients With Non-Valvular A-Fib In VA Patients With Medicare". The overall objective of this analysis is to understand patient characteristics, the use of treatment, and clinical outcomes among obese (overweight) and severely obese patients with non-valvular atrial fibrillation (NVAF) who initiate therapy with OACs (oral anti-coagulants). The aim of this study ...
What is the current status of trial NCT04681482?
This trial is currently completed. The enrollment target is 107,383 participants. The study started on 2020-11-02. Estimated completion is 2020-11-03.
What interventions are being tested in trial NCT04681482?
The interventions under investigation include: Apixaban (DRUG).
Who is sponsoring clinical trial NCT04681482?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05804188 · 105,000 participants
CRICKET: Critical Events in Anaesthetised Kids Undergoing Tracheal Intubation
- NCT02917460 · 102,000 participants · NA
Rady Children's Institute Genomic Biorepository
- NCT05741112 · 100,500 participants · NA
The Long COVID-19 Wearable Device Study
- NCT02620852 · 100,000 participants · NA
Women Informed to Screen Depending on Measures of Risk (Wisdom Study)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI